Working... Menu

Study of Venetoclax With the mIDH1 Inhibitor Ivosidenib (AG120) in IDH1-Mutated Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03471260
Recruitment Status : Recruiting
First Posted : March 20, 2018
Last Update Posted : January 7, 2019
Agios Pharmaceuticals, Inc.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : September 2019
  Estimated Study Completion Date : September 2019